SCYNEXIS to Participate in Piper Sandler and Evercore ISI Conferences
JERSEY CITY, N.J., Nov. 24, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the Company’s participation in Piper Sandler’s 32^nd Annual Virtual Healthcare Conference. Presentations will be available for registered attendees via the Piper Sandler conference site from November 23 to December 3, 2020. The Company will also participate in a panel discussion at Evercore ISI’s 3^rd Annual HealthCONx Conference taking place on December 2, 2020.*Presentation details**:*
*Piper Sandler 32*^*nd** Annual Virtual Healthcare Conference:*
Presentation Date: Monday, November 23 to Thursday, December 3, 2020
Presentation Time: 8:00 a.m. – 5:00 p.m. ET
Webcast:
Link
*Evercore ISI 3*^*rd** Annual HealthCONx Conference**:*
Panel Discussion Topic:
No Fungus Among Us: Addressing an Important Need with Cidara, F2G, and SCYNEXIS
Presentation Date: Wednesday, December 2, 2020
Presentation Time: 11:20 a.m. – 12:05 p.m. ET
A webcast of both presentation recordings will be available for 30 days and can be found on the Scynexis website at: https://www.scynexis.com/news-media/events.
*About SCYNEXIS*
SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to potentially help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. Our lead candidate, ibrexafungerp (formerly known as SCY-078), is a broad-spectrum, IV/oral antifungal agent representing a novel therapeutic class, in late stage development for multiple indications, ranging from vaginal yeast infections to life-threatening fungal infections in hospitalized patients. The SCYNEXIS team has deep expertise in anti-infective drug development and marketing, which can be leveraged to advance ibrexafungerp from clinical development to commercialization. For more information, visit www.scynexis.com.
*CONTACT**: *
*Investor Relations*
Irina Koffler
LifeSci Advisors
Tel: (646) 970-4681
ikoffler@lifesciadvisors.com
*Media Relations*
Gloria Gasaatura
LifeSci Communications
Tel: (646) 970-4688
ggasaatura@lifescicomms.com